Verastem (VSTM) Return on Capital Employed (2012 - 2026)
Verastem (VSTM) recorded quarterly Return on Capital Employed of 26.26% in Q1 2026, up 16.8% quarter-over-quarter from 31.56% in Q4 2025, and up 13556.0% on a YoY basis from N/an in Q1 2025.
Verastem (VSTM) Return on Capital Employed (2012 - 2026) Analysis & Trends
Verastem's Return on Capital Employed history runs 15 years deep, the most recent figure standing at 26.26% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 13556.0% year-over-year to 26.26%; the TTM figure through Mar 2026 stood at 26.26% (up 13556.0% YoY), while the FY2025 annual figure was 43.24%, up 7820.0% from the prior year.
- Return on Capital Employed was 26.26% for Q1 2026 at Verastem, up from 31.56% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 26.26% in Q1 2026 to a low of 161.82% in Q1 2025.
- Historically, Return on Capital Employed has averaged 91.64% across 5 years, with a median of 87.96% in 2023.
- The sharpest annual moves came in 2024 and 2026: Return on Capital Employed tumbled 9694 bps in 2024, then soared 13556 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 89.59% in 2022, then increased by 25 bps to 67.43% in 2023, then tumbled by 105 bps to 138.53% in 2024, then soared by 77 bps to 31.56% in 2025, then increased by 17 bps to 26.26% in 2026.
- The last three Return on Capital Employed figures came in at 26.26% (Q1 2026), 31.56% (Q4 2025), and 126.33% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Verastem | 407.42 Mn | 225.74 Mn | 15.90 Mn | -26.26% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.26% |
| Dec 31, 2025 | -31.56% |
| Sep 30, 2025 | -126.33% |
| Jun 30, 2025 | -137.79% |
| Mar 31, 2025 | -161.82% |
| Dec 31, 2024 | -138.53% |
| Sep 30, 2024 | -145.52% |
| Jun 30, 2024 | -117.19% |
| Mar 31, 2024 | -91.72% |
| Dec 31, 2023 | -67.43% |
| Sep 30, 2023 | -48.58% |
| Jun 30, 2023 | -54.74% |
| Mar 31, 2023 | -87.96% |
| Dec 31, 2022 | -89.59% |
| Sep 30, 2022 | -86.56% |
| Jun 30, 2022 | -79.08% |
| Mar 31, 2022 | -67.30% |
| Dec 31, 2021 | -66.98% |
| Sep 30, 2021 | -59.08% |
| Jun 30, 2021 | -27.02% |